<p>在不确定性中，医疗保健股为投资者提供了一个避风港。</p>
<p>美联储决定将利率维持在 5.25% 至 5.5% 的 23 年高位，以应对持续的通货膨胀。根据美联储的说法，当前经济前景仍不确定，委员会对通货膨胀风险保持警惕。</p>
<p>此外，最近一份黑石集团的报告强调，美国医疗保健股在过去七次衰退中平均表现比整体市场出色 10%。</p>
<p>也因此，该文章介绍了三家目前值得购买的医疗保健股。这些企业以其创新的产品管道和在医疗技术领域的强劲市场地位脱颖而出。此外，每家公司都准备通过技术进步实现强劲增长，提升其获得更大市场份额和更强盈利能力的潜力。</p>
<p>因此，现在比以往任何时候都更应选择医疗保健股，它们代表了面对经济不确定性的坚定选择。</p>
<h2>现在购买的医疗保健股：美敦力（MDT）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>图片来源：JHVEPhoto / Shutterstock.com</p>
<p><strong>美敦力</strong>（纽约证券交易所：<strong>MDT</strong>）是医疗科技领域的明星选择，平衡了稳定性和增长机会。尽管它并非增长最快的财富复利者，但在其所在领域的悠久历史和稳健的股息配置方面仍然表现出色。其丰厚的股息收益率超过 3.5%，已经连续维持了十多年。此外，凭借超过 122 亿美元的自由现金流，它有足够的实力继续增加股息。</p>
<p>MDT 以多款产品脱颖而出，是顶尖的纯医疗器械制造商。特别在糖尿病护理领域表现突出，在 2022 财年达到 23.4 亿美元的四年低点后，见证了巨大的转变。在 2024 财年第四季度，糖尿病产品的季度收入达到 6.6 亿美元，比去年同期增长 11%。其第四季度报告延续了第三季度的增长势头，销售额激增 12.3%，达到 6.4 亿美元。</p>
<p>此外，在 CEO Geoff Martha 的积极领导下，MDT 正致力于在医疗保健领域开创人工智能的战略整合。目标是显著提升临床决策能力，同时促进新治疗指标的发展。总体而言，这种创新优势为投资 MDT 股票提供了引人注目的理由。</p>
<h2>Kenvue（KVUE）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>图片来源：shutterstock.com/T. Schneider</p>
<p><strong>Kenvue</strong>（纽约证券交易所：<strong>KVUE</strong>）是几年前由医疗巨头 <strong>强生</strong>（纽约证券交易所：<strong>JNJ</strong>）孵化而生，现已成为按收入计算最大的纯消费者健康公司。凭借超过 150 亿美元的收入，Kenvue 拥有一系列经典的消费者健康品牌，如泰诺、李施德林和邦迪。这些品牌拥有非弹性需求，保持在高通货膨胀中的强劲地位。</p>
<p>其最近一个季度的销售额相对稳定，第一季度销售额增长了 1.1%，达到 39 亿美元。销售量有所下降，但其中很大一部分可以归因于去年的库存积压。</p>
<p>与 MDT 类似，Kenvue 股票也一直是一种平淡的财富复利者。然而，由于其令人印象深刻的股息配置，股息率超过 4.3%，它继续吸引投资者。因此，对于正在寻找引人注目、防御性、不受衰退影响的投资者来说，KVUE 股票是一个不错的选择。此外，该股票以 2.21 倍的预期销售额和 2.7 倍的预期企业价值交易。</p>
<h2>直觉外科（ISRG）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>图片来源：Sundry Photography / Shutterstock.com</p>
<p><strong>直觉外科</strong>（纳斯达克：<strong>ISRG</strong>）是在机器人辅助手术领域的先驱，拥有开创性的达芬奇外科系统。这些系统在医疗保健领域具有革命性意义，促进了超过 1300 万次手术。</p>
<p>ISRG 一直在良好的增长轨道上，系统安装量大幅增加，从上一年的 1,264 台增至 1,370 台。此外，在第一季度，公司实现了强劲的收入增长，达到了惊人的 19 亿美元，较去年同期增长 11%。这一增长与达芬奇手术的全球增长 16% 有关，反映了从疫情导致的放缓中出色复苏和清理积压。</p>
<p>此外，其第一季度净收入大幅增长 5.474 亿美元，较去年同期的 3.608 亿美元增长。这些数字在收入和利润两方面均大幅超出分析师的预期，预示着 ISRG 在继续创新和扩大临床应用方面有着光明的未来。此外，与名单上其他公司不同，ISRG 股票一直是一种巨大的财富复利者。在过去五年中上涨了 157%，在过去一年中增长了超过 30%。</p>
<p><em>在发布日期，Muslim Farooque 在本文提到的证券中没有（直接或间接）任何头寸。本文中表达的观点属于作者本人，受到 InvestorPlace.com 发布指南的约束</em></p>
<p>Muslim Farooque 是一位热心的投资者，内心充满乐观。作为一名终身游戏玩家和科技爱好者，他特别喜欢分析科技股。Muslim 拥有牛津布鲁克斯大学应用会计学学士学位。</p>
<p>医疗保健</p>

KVUE

直觉外科

美敦力

<p>在经济不确定性中，医疗保健股被认为是投资者的避风港。该文章重点介绍了三只当前值得购买的医疗保健股，包括美敦力（Medtronic）、康维（Kenvue）和直觉外科（Intuitive Surgical）。美敦力是一家顶尖的医疗器械制造商，具有强大的股息概况。康维是最大的纯消费者健康公司，拥有经典品牌。直觉外科是机器人辅助手术领域的领导者。这些股票提供创新产品，并在医疗技术领域拥有强劲的市场地位</p>

<p>Healthcare stocks offer a haven for investors amidst the uncertainty.</p>
<div class="lb-trans"><p>在不确定性中，医疗保健股为投资者提供了一个避风港。</p>
</div><p>The Fed elected to hold interest rates at a 23-year high between 5.25% and 5.5% to combat persistent inflation. According to the Fed, the current economic outlook remains uncertain, and the Committee remains alert to inflationary headwinds.</p>
<div class="lb-trans"><p>美联储决定将利率维持在 5.25% 至 5.5% 的 23 年高位，以应对持续的通货膨胀。根据美联储的说法，当前经济前景仍不确定，委员会对通货膨胀风险保持警惕。</p>
</div><p>Additionally, a recent BlackRock report highlights that U.S. healthcare stocks have impressively outshone the broader market by an average of 10% across the last seven recessions.</p>
<div class="lb-trans"><p>此外，最近一份黑石集团的报告强调，美国医疗保健股在过去七次衰退中平均表现比整体市场出色 10%。</p>
</div><p>That said, the article covers three of the best healthcare stocks to buy now. These businesses stand out for their innovative product pipelines and strong market positions in medical technology. Moreover, each company is poised for robust growth through tech advancements, enhancing its potential for greater market share and stronger profitability.</p>
<div class="lb-trans"><p>也因此，该文章介绍了三家目前值得购买的医疗保健股。这些企业以其创新的产品管道和在医疗技术领域的强劲市场地位脱颖而出。此外，每家公司都准备通过技术进步实现强劲增长，提升其获得更大市场份额和更强盈利能力的潜力。</p>
</div><p>Hence, now more than ever, healthcare stocks represent resilient picks for those facing economic uncertainty.</p>
<div class="lb-trans"><p>因此，现在比以往任何时候都更应选择医疗保健股，它们代表了面对经济不确定性的坚定选择。</p>
</div><h2>Healthcare Stocks to Buy Now: Medtronic (MDT)</h2>
<div class="lb-trans"><h2>现在购买的医疗保健股：美敦力（MDT）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: JHVEPhoto / Shutterstock.com</p>
<div class="lb-trans"><p>图片来源：JHVEPhoto / Shutterstock.com</p>
</div><p><strong>Medtronic</strong>(NYSE: <strong>MDT</strong>) is a standout pick in MedTech, balancing stability with growth opportunities. Though it hasn’t been the biggest wealth compounder, it continues to shine with its storied history in its niche and a solid dividend profile. Its rewarding dividend yield, exceeding 3.5%, has been sustained for over a decade. Moreover, with north of $12.2 billion in free cash flows, it has enough in the tank to continue growing its payouts.</p>
<div class="lb-trans"><p><strong>美敦力</strong>（纽约证券交易所：<strong>MDT</strong>）是医疗科技领域的明星选择，平衡了稳定性和增长机会。尽管它并非增长最快的财富复利者，但在其所在领域的悠久历史和稳健的股息配置方面仍然表现出色。其丰厚的股息收益率超过 3.5%，已经连续维持了十多年。此外，凭借超过 122 亿美元的自由现金流，它有足够的实力继续增加股息。</p>
</div><p>MDT distinguishes itself as a top pure-play medical device maker with multiple products to boot. It stands tall, particularly in diabetes care, witnessing a massive turnaround after hitting a four-year low of $2.34 billion in fiscal year (FY) 2022. In its FY 2024 fourth-quarter (Q4), quarterly diabetes revenues were at $660 million, an 11% increase from the prior-year quarter. Its Q4 report maintained its form following a third-quarter (Q3) surge, with sales rocketing 12.3% to $640 million.</p>
<div class="lb-trans"><p>MDT 以多款产品脱颖而出，是顶尖的纯医疗器械制造商。特别在糖尿病护理领域表现突出，在 2022 财年达到 23.4 亿美元的四年低点后，见证了巨大的转变。在 2024 财年第四季度，糖尿病产品的季度收入达到 6.6 亿美元，比去年同期增长 11%。其第四季度报告延续了第三季度的增长势头，销售额激增 12.3%，达到 6.4 亿美元。</p>
</div><p>Moreover, under the dynamic leadership of CEO Geoff Martha, MDT is looking to pioneer the strategic integration of AI in healthcare. The goal is to significantly enhance clinical decision-making while fostering the development of new treatment indicators. Overall, this innovative edge presents a compelling case for investing in MDT stock.</p>
<div class="lb-trans"><p>此外，在 CEO Geoff Martha 的积极领导下，MDT 正致力于在医疗保健领域开创人工智能的战略整合。目标是显著提升临床决策能力，同时促进新治疗指标的发展。总体而言，这种创新优势为投资 MDT 股票提供了引人注目的理由。</p>
</div><h2>Kenvue (KVUE)</h2>
<div class="lb-trans"><h2>Kenvue（KVUE）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: shutterstock.com/T. Schneider</p>
<div class="lb-trans"><p>图片来源：shutterstock.com/T. Schneider</p>
</div><p><strong>Kenvue</strong>(NYSE: <strong>KVUE</strong>), born from healthcare juggernaut <strong>Johnson &amp; Johnson</strong> (NYSE: <strong>JNJ</strong>) a couple of years ago, is now the largest pure-play consumer health company by revenue. With revenues exceeding the $15 billion mark, Kenvue boasts a lineup of timeless consumer health brands such as Tylenol, Listerine, and Band-Aid. These brands flaunt inelastic demand, maintaining their robust positioning amid soaring inflation.</p>
<div class="lb-trans"><p><strong>Kenvue</strong>（纽约证券交易所：<strong>KVUE</strong>）是几年前由医疗巨头 <strong>强生</strong>（纽约证券交易所：<strong>JNJ</strong>）孵化而生，现已成为按收入计算最大的纯消费者健康公司。凭借超过 150 亿美元的收入，Kenvue 拥有一系列经典的消费者健康品牌，如泰诺、李施德林和邦迪。这些品牌拥有非弹性需求，保持在高通货膨胀中的强劲地位。</p>
</div><p>Its most recent quarter saw a relatively modest 1.1% increase in first-quarter (Q1) sales to $3.9 billion. Sales volumes were down, but a lot of it can be attributed to last year’s inventory build-up.</p>
<div class="lb-trans"><p>其最近一个季度的销售额相对稳定，第一季度销售额增长了 1.1%，达到 39 亿美元。销售量有所下降，但其中很大一部分可以归因于去年的库存积压。</p>
</div><p>Like MDT, Kenvue stock has also been a lackluster wealth compounder. However, it continues to attract investors for its impressive dividend profile, yielding over 4.3%. Hence, for investors on the lookout for a compelling, defensive, recession-proof investment, look no further than KVUE stock. Also, the stock trades at 2.21 times forward sales estimates and 2.7 times its forward enterprise value.</p>
<div class="lb-trans"><p>与 MDT 类似，Kenvue 股票也一直是一种平淡的财富复利者。然而，由于其令人印象深刻的股息配置，股息率超过 4.3%，它继续吸引投资者。因此，对于正在寻找引人注目、防御性、不受衰退影响的投资者来说，KVUE 股票是一个不错的选择。此外，该股票以 2.21 倍的预期销售额和 2.7 倍的预期企业价值交易。</p>
</div><h2>Intuitive Surgical (ISRG)</h2>
<div class="lb-trans"><h2>直觉外科（ISRG）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Sundry Photography / Shutterstock.com</p>
<div class="lb-trans"><p>图片来源：Sundry Photography / Shutterstock.com</p>
</div><p><strong>Intuitive Surgical</strong>(NASDAQ: <strong>ISRG</strong>) is a forerunner in robotic-assisted surgery with its pioneering da Vinci Surgical Systems. These systems have proven revolutionary in healthcare and facilitate over 13 million procedures.</p>
<div class="lb-trans"><p><strong>直觉外科</strong>（纳斯达克：<strong>ISRG</strong>）是在机器人辅助手术领域的先驱，拥有开创性的达芬奇外科系统。这些系统在医疗保健领域具有革命性意义，促进了超过 1300 万次手术。</p>
</div><p>ISRG has been on an excellent growth trajectory, witnessing a strong uptick in system placements, installing 1,370 units, up from 1,264 the previous year. Moreover, in Q1, the company posted stellar revenues, reaching a mighty impressive $1.9 billion, marking an 11% bump from the prior-year period. This surge is linked to a 16% global increase in da Vinci procedures, reflecting a superb rebound from the pandemic-led slowdown and a cleared backlog.</p>
<div class="lb-trans"><p>ISRG 一直在良好的增长轨道上，系统安装量大幅增加，从上一年的 1,264 台增至 1,370 台。此外，在第一季度，公司实现了强劲的收入增长，达到了惊人的 19 亿美元，较去年同期增长 11%。这一增长与达芬奇手术的全球增长 16% 有关，反映了从疫情导致的放缓中出色复苏和清理积压。</p>
</div><p>Moreover, its Q1 net income jumped impressively by $547.4 million, up from $360.8 million in the same period last year. These figures comfortably beat analyst expectations on both top and bottom lines while signaling a bright future for ISRG as it continues to innovate and expand its clinical applications. Also, unlike others on the list, ISRG stock has been a tremendous wealth compounder. It’s up 157% in the past five years and more than 30% in the past year.</p>
<div class="lb-trans"><p>此外，其第一季度净收入大幅增长 5.474 亿美元，较去年同期的 3.608 亿美元增长。这些数字在收入和利润两方面均大幅超出分析师的预期，预示着 ISRG 在继续创新和扩大临床应用方面有着光明的未来。此外，与名单上其他公司不同，ISRG 股票一直是一种巨大的财富复利者。在过去五年中上涨了 157%，在过去一年中增长了超过 30%。</p>
</div><p><em>On the date of publication, Muslim Farooque did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines</em></p>
<div class="lb-trans"><p><em>在发布日期，Muslim Farooque 在本文提到的证券中没有（直接或间接）任何头寸。本文中表达的观点属于作者本人，受到 InvestorPlace.com 发布指南的约束</em></p>
</div><p>Muslim Farooque is a keen investor and an optimist at heart. A life-long gamer and tech enthusiast, he has a particular affinity for analyzing technology stocks. Muslim holds a bachelor’s of science degree in applied accounting from Oxford Brookes University.</p>
<div class="lb-trans"><p>Muslim Farooque 是一位热心的投资者，内心充满乐观。作为一名终身游戏玩家和科技爱好者，他特别喜欢分析科技股。Muslim 拥有牛津布鲁克斯大学应用会计学学士学位。</p>
</div><p>Healthcare</p>
<div class="lb-trans"><p>医疗保健</p>
</div>

2024 年 6 月值得购买的三只医疗保健股票